Source comparison
Men 25-35 BPC-157 Protocol: Administration Comparison
Daily Dose 250mcg once daily 500mcg once daily OR 250mcg twice daily 500mcg twice daily (1000mcg total) Doses above 500mcg daily show no additional efficacy in trials and increase injection site reaction risk. Reserve aggressive dosing only for severe acute in
This comparison does not assign a generated winner or score.
- Daily Dose
- 250mcg once daily
- 500mcg once daily OR 250mcg twice daily
- 500mcg twice daily (1000mcg total)
- Doses above 500mcg daily show no additional efficacy in trials and increase injection site reaction risk. Reserve aggressive dosing only for severe acute injuries under medical supervision
- Cycle Length
- 4 weeks
- 6 weeks
- 8 weeks
- Longer cycles (beyond 8 weeks) without breaks cause receptor desensitization. Most injuries transition out of active inflammatory/proliferative phase by week 6-8
- Injection Site
- Systemic (abdominal subQ)
- Local (within 2-4 inches of injury)
- Local + systemic split dosing
- Local injection front-loads peptide concentration at injury site during first-pass. Systemic works but is less efficient for localized injuries
- Washout Period
- Equal to cycle length
- 1.5× cycle length
- 2× cycle length
- Minimum washout = cycle length. Longer washouts preserve receptor sensitivity for future cycles. Critical for athletes with recurring injury patterns
- Reconstitution Volume
- 2ml bacteriostatic water per 5mg vial
- 1ml bacteriostatic water per 5mg vial (higher concentration)
- Higher concentration reduces injection volume but increases peptide density per ml. Choose based on injection comfort preference, not efficacy
- Storage Compliance
- Refrigerated 2-8°C, discard after 28 days
- Refrigerated 2-8°C, extend to 35 days if sterility maintained
- Temperature excursions above 8°C denature peptide irreversibly. 28-day discard window is conservative but safe. Extending beyond that increases contamination risk in multi-dose vials